Onconetix Issues Promissory Note to Keystone Capital

Onconetix ( (ONCO) ) just unveiled an announcement.

On June 5, 2025, Onconetix, Inc. issued a promissory note to Keystone Capital Partners, LLC, with a principal amount of $147,058.82, to be repaid by March 5, 2026, or upon receipt of sufficient proceeds from other securities offerings. Additionally, Onconetix announced a 1-for-85 reverse stock split approved by its stockholders on May 30, 2025, to regain compliance with Nasdaq’s minimum bid price requirement. The reverse stock split will reduce the number of outstanding shares from approximately 44.4 million to about 521,863, taking effect on June 13, 2025.

Spark’s Take on ONCO Stock

According to Spark, TipRanks’ AI Analyst, ONCO is a Underperform.

Onconetix’s overall score reflects substantial financial difficulties with significant operating losses and negative profitability metrics. The technical analysis suggests a bearish trend, and the valuation metrics are unfavorable due to negative earnings. These factors combine to give the stock a low attractiveness score.

To see Spark’s full report on ONCO stock, click here.

More about Onconetix

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, and ENTADFI, an FDA-approved treatment for benign prostatic hyperplasia.

Average Trading Volume: 22,933,430

Technical Sentiment Signal: Sell

Current Market Cap: $3.63M

Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.